Mani Mohindru

Dr. Mohindru is an experienced biotech executive with several years of biopharmaceutical industry leadership as well as Wall Street experience. Currently she is a member of the Board of Directors of CytomX Therapeutics (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company and SAB Biotherapeutics, a clinical-stage biopharmaceutical company advancing a new class of immunotherapies. Most recently she was the CEO of CereXis, Inc., a biotech company focused on rare tumor indications. Previously, she was the Chief Financial Officer and Chief Strategy Officer at Cara Therapeutics (Nasdaq: CARA) and Chief Strategy Officer at Curis, Inc. (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent multiple years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. She also co-founded Immtox LLC, a privately held biotechnology company, and was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health). Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and her Masters in Biotechnology and BS in Human Biology (Hons) from the All India Institute of Medical Sciences, India.